Digital gangrene associated with idiopathic hypereosinophilia: Treatment with allogeneic cultured dermal substitute (CDS)

European Journal of Dermatology

Volumn 14, Issue 3, 2004, Pages 168-171

  Ohtani, Toshio ^a   Okamoto, Katsuyuki ^a   Kaminaka, Chikako ^a   Kishi, Tomoh ^a   Sakurane, Mikihisa ^a   Yamamoto, Yuki ^a   Uede, Koji ^a   Kubo, Kentaro ^b   Kuroyanagi, Yoshimitsu ^b   Furukawa, Fukumi ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY   (Japan)

Author keywords

Allogeneic cultured dermal substitute; Gangrene; Hypereosinophilic syndrome; Vasculitis

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTITHROMBOCYTIC AGENT; COLLAGEN; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE; HYALURONIC ACID; PREDNISOLONE; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR; VASCULOTROPIN; VASODILATOR AGENT;

AGED; ALLERGY; ALLOGRAFT; AMPUTATION; ANAMNESIS; ARTERIOLE; ARTICLE; CASE REPORT; CELL CULTURE; CONNECTIVE TISSUE; CYTOKINE RELEASE; DIAGNOSTIC PROCEDURE; FIBROBLAST; GANGRENE; HISTOPATHOLOGY; HUMAN; HYPEREOSINOPHILIA; LABORATORY TEST; MALE; NEOPLASM; PARASITOSIS; PHYSICAL EXAMINATION; SKIN DEFECT; TREATMENT OUTCOME; VASCULITIS;

AGED; AMPUTATION; DIAGNOSIS, DIFFERENTIAL; FINGERS; GANGRENE; HUMANS; HYPEREOSINOPHILIC SYNDROME; MALE; SKIN, ARTIFICIAL; TOES;

EID: 2942616798     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Leiferman KM. Cutaneous eosinophilic diseases. In: Freedberg IM, Eiesn AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, Fitzpatrick TB, eds. Dermatology in General Medicine, 5th ed, New York: McGraw-Hill, 1999: 1129-37.
2. Jang KA, Lim YS, Choi JH, Sung KJ, Moon KC, Koh JK. Hypereosinophilic syndrome presenting as cutaneous necrotizing eosinophilic vasculitis and Raynaud's phenomenon complicated by digital gangrene. Br J Dermatol 2000; 143: 641-4.
3. Green H, Kehinde O, Thomas J. Growth of cultured human epidermal cells into multiple epithelia suitable far grafting. Proc Natl Acad Sci USA 1979; 76: 5665-8.
4. Bell E, Ehrlich HP, Sher S, Merrill C, Sarber R, Hull B, Nakatsuji T, Church D, Buttle DJ. Development and use of a living skin equivalent. Plast Reconstr Surg 1981; 67: 386-92.
5. Cooper ML, Hansbrough JF, Spielvogel RL, Cohen R, Bartel RI, Naughton G. In vivo optimization of a living dermal substitute employing cultured human fibroblasts on a biodegradable polyglycolic acid or polyglactin mesh. Biomaterials 1991; 12: 243-8.
6. Hansbrough JF, Morgan J, Greenleaf G. Development of a temporary living skin replacement composed of human neonatal fibroblasts cultured in Biobrane, a synthetic dressing material. Surgery 1994; 115: 633-44.
7. O'Connor NE, Muliken JG, Banks-Schlegel S, Kehinde O, Green H. Grafting of burns with cultured epithelium prepared from autologous epidermal cells. Lancet 1982; 1: 75-8.
8. Gallica GG, O'Connor NE, Compton CC, Kehinde O, Green H. Permanent coverage of large burn wounds with autologous cultured human epithelium. N Engl J Med 1984; 311: 448-51.
9. Hansbrough JF, Christine D, Hansbrough WB. Clinical trials of a living dermal tissue replacement placed beneath meshed, split-thickness skin grafts on excised burn wounds. J Burn Care Rehabil 1992; 13: 519-29.
10. Gentzkow GD, Iwasaki SD, Hershan KS, Mengel M, Prendergast JJ, Ricotta JJ, Steed DP, Lipkin S. Use of Dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care 1996; 19: 350-4.
11. Hansbrough JF, Mozinga DW, Kealey GP, Davis M, Gidner A, Gentzkow GD. Clinical trials of a biasynthetic temporary skin replacement, Dermagraft-Transitional Coverage, compared with cryo-preserved human cadaver skin for temporary coverage of excised burn wounds. J Burn Care Rehabil 1997; 18: 43-51.
12. Parenteau N. Skin: the first tissue-engineered products. The Organogenesis Story, Scientific American 1999; April, 59-60.
13. Kuroyanagi Y, Yamada N, Yamashita R, Uchinuma E. Tissue-engineered product: allogenic cultured dermal substitute composed of spongy collagen with fibroblasts. Artificial Organs 2001; 25: 180-6.
14. Kuroyanogi Y, Kubo K, Matsui H, Kagawa S, Mori S, Kim HJ, Mabuchi Y. Manufacturing and banking system for allogeneic cultured dermal substitute. Jpn J Burn Injuries 2003; 29: 28-38.
15. Kubo K, Kuroyanagi Y. Spongy matrix of hyaluronic acid and collagen as a cultured dermal substitute: evaluation in an animal test. J of Artif Organs 2003; 6: 64-70.
16. Benedetti L, Cortivo R, Berti T, Berti A, Pea F, Mazzo M, Moras M, Abatangelo G. Biocompatibility and biodegradation of different hyaluronan derivatives (Hyaff) implanted in rats. Biomater 1993; 14: 1154-60.
17. Postlethwaite AE, Seyer JM, Kang AH. Chemotactic attraction of human fibroblasts to type I, II, and III collagens and collagen-derived peptides. Proc Natl Acad Sci USA 1978; 75: 871-5.
18. Oka H, Fujitsu M, Suenobu K, Moriguchi T, Kubo K, Matsui H, Kagawa S, Kuroyanagi Y: Clinical trials with allogeneic cultured dermal substitute (CDS) for the treatment of burns and skin ulcers. Jpn J Burn Injuries 2002; 28: 333-42.
19. Harima N, Ansai S, Wako M, Manabe M, Kubo K, Matsui H, Kagawa S, Kuroyanagi Y: Clinical trials using allogeneic cultured dermal substitutes for skin ulcers. Jpn J Dermatology 2003; 113: 253-64.
20. Oppliger R, Gay-Crosier F, E Dayer, Hauser C. Digital necrosis in a patient with hypereosinophilic syndrome in the absence of cutaneous eosinophilic vasculitis. Br J Dermatol 2001; 144: 1087-9.
21. Takekawa M, Imai K, Adachi M, Aoki S, Maeda K, Hinoda Y, Yachi A. Hypereosinophilic syndrome accompanied with necrosis of finger tips. Intern Med 1992; 31: 1262-6.
22. Ferguson GT, Starkebaum G. Thromboangiitis obliterans associated with idiapathic hypereosinophilia. Arch Intern Med 1985; 145: 1726-8.
23. Aractingi S, Bachmeyer C. Necrotic cutaneous lesions induced by hypereosinophilic syndrome secondary to o T-cell lymphoma. J Am Acad Dermatol 2001; 46: S133-6.
24. Slungaard A, Vercellotti GM, Tran T, Gleich GJ, Key NS. Eosinophil cationic granule proteins impair thrombomodulin function. J Clin Invest 1993: 91: 1721-30.
25. Yamamato-Mukai H, Ninomiya H, Ohtani K, Nagasawa T, Abe T. Major basic protein binding to thrombomodulin potentially contributes to the thrombosis in patients with eosinophilia. Br J Haematol 1995; 90: 892-9.
26. Gleich GJ, Leiferman KM, Pardanai A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 2002; 359: 1577-8.
27. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Courte SE, Stone R, Gilliland DG. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypersensitivity syndrome. N Engl J Med 2003; 348: 1201-14.